SI0804436T1 - Derivat gvanina - Google Patents

Derivat gvanina

Info

Publication number
SI0804436T1
SI0804436T1 SI9630717T SI9630717T SI0804436T1 SI 0804436 T1 SI0804436 T1 SI 0804436T1 SI 9630717 T SI9630717 T SI 9630717T SI 9630717 T SI9630717 T SI 9630717T SI 0804436 T1 SI0804436 T1 SI 0804436T1
Authority
SI
Slovenia
Prior art keywords
guanine derivative
guanine
derivative
Prior art date
Application number
SI9630717T
Other languages
English (en)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter G Varlashkin
Richard Augustus Winnike
William Bayne Grubb Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0804436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SI0804436T1 publication Critical patent/SI0804436T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
SI9630717T 1995-01-20 1996-01-19 Derivat gvanina SI0804436T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative
EP96900631A EP0804436B1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
SI0804436T1 true SI0804436T1 (sl) 2006-02-28

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630717T SI0804436T1 (sl) 1995-01-20 1996-01-19 Derivat gvanina

Country Status (40)

Country Link
US (1) US6107302A (sl)
EP (1) EP0804436B1 (sl)
JP (1) JP3176633B2 (sl)
KR (1) KR100376074B1 (sl)
CN (1) CN1049893C (sl)
AP (1) AP662A (sl)
AR (1) AR002270A1 (sl)
AT (1) ATE302777T1 (sl)
AU (1) AU702794B2 (sl)
BG (1) BG63393B1 (sl)
BR (1) BR9606768A (sl)
CA (1) CA2210799C (sl)
CY (1) CY2531B1 (sl)
CZ (1) CZ297065B6 (sl)
DE (1) DE69635106T2 (sl)
DK (1) DK0804436T3 (sl)
EA (1) EA000364B1 (sl)
EE (1) EE03528B1 (sl)
ES (1) ES2248806T3 (sl)
FI (1) FI973063A (sl)
GB (1) GB9501178D0 (sl)
GE (1) GEP20001940B (sl)
HR (1) HRP960024B1 (sl)
HU (1) HU222993B1 (sl)
IL (1) IL116831A (sl)
IN (1) IN182468B (sl)
IS (1) IS2268B (sl)
NO (1) NO315558B1 (sl)
NZ (1) NZ298851A (sl)
OA (1) OA10499A (sl)
PL (1) PL182175B1 (sl)
RO (1) RO118693B1 (sl)
RS (1) RS49518B (sl)
SI (1) SI0804436T1 (sl)
SK (1) SK285329B6 (sl)
TR (1) TR199700656T1 (sl)
UA (1) UA46001C2 (sl)
UY (1) UY25779A1 (sl)
WO (1) WO1996022291A1 (sl)
ZA (1) ZA96449B (sl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6849736B2 (en) * 2001-09-07 2005-02-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
KR20070020149A (ko) * 2001-11-14 2007-02-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르의 합성 및 정제 방법
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006011874A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries, Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
EP0702682B1 (en) * 1993-06-10 2001-03-14 Rolabo Sl Process for the preparation of amino acid esters of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
EP0804436A1 (en) 1997-11-05
HU222993B1 (hu) 2004-01-28
DE69635106D1 (de) 2005-09-29
NO973326D0 (no) 1997-07-18
GB9501178D0 (en) 1995-03-08
AU702794B2 (en) 1999-03-04
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
IN182468B (sl) 1999-04-17
MX9705462A (es) 1997-10-31
FI973063A0 (fi) 1997-07-18
CZ229497A3 (en) 1997-12-17
CA2210799C (en) 2008-06-10
KR100376074B1 (ko) 2003-06-02
HUP9801836A2 (hu) 1999-05-28
HRP960024A2 (en) 1997-10-31
EP0804436B1 (en) 2005-08-24
IS2268B (is) 2007-07-15
AP662A (en) 1998-08-19
FI973063A (fi) 1997-09-18
CA2210799A1 (en) 1996-07-25
CN1179159A (zh) 1998-04-15
NO973326L (no) 1997-09-16
RS49518B (sr) 2006-10-27
BR9606768A (pt) 1997-12-30
SK285329B6 (sk) 2006-11-03
AP9701058A0 (en) 1997-10-31
AR002270A1 (es) 1998-03-11
ATE302777T1 (de) 2005-09-15
HRP960024B1 (en) 2005-08-31
CY2531B1 (en) 2006-04-12
YU3396A (sh) 1998-12-23
CZ297065B6 (cs) 2006-08-16
OA10499A (en) 2002-04-10
NZ298851A (en) 1999-01-28
NO315558B1 (no) 2003-09-22
EE9700175A (et) 1998-02-16
SK96597A3 (en) 1998-02-04
ZA96449B (en) 1996-08-07
TR199700656T1 (xx) 1998-03-21
BG101833A (en) 1998-04-30
EA000364B1 (ru) 1999-06-24
IL116831A0 (en) 1996-05-14
IL116831A (en) 1998-10-30
UY25779A1 (es) 2000-08-21
JPH11503718A (ja) 1999-03-30
EA199700124A1 (ru) 1997-12-30
GEP20001940B (en) 2000-02-05
US6107302A (en) 2000-08-22
PL321326A1 (en) 1997-12-08
IS4527A (is) 1997-07-15
DK0804436T3 (da) 2005-12-27
AU4453996A (en) 1996-08-07
RO118693B1 (ro) 2003-09-30
DE69635106T2 (de) 2006-06-08
HUP9801836A3 (en) 1999-06-28
KR19980701525A (ko) 1998-05-15
JP3176633B2 (ja) 2001-06-18
EE03528B1 (et) 2001-10-15
WO1996022291A1 (en) 1996-07-25
ES2248806T3 (es) 2006-03-16
UA46001C2 (uk) 2002-05-15
PL182175B1 (pl) 2001-11-30

Similar Documents

Publication Publication Date Title
CY2531B1 (en) Guanine derivative
GB9508565D0 (en) Quiazoline derivative
NZ305444A (en) 4-anilino-7-alkoxy-quinazoline derivatives
IL152383A0 (en) 5-amino-3-cyano-4-ethylsulfinyl-1- phenyl-pyrazole derivatives
IL135376A0 (en) Hydroxyalkyl-phenyl derivatives
GB2306473A8 (en) Glucoxide derivatives
ZA96228B (en) Indolepiperidine derivatives
ZA969278B (en) Purin-6-one derivatives
HU9600876D0 (en) Benzonitril- and -fluoride derivatives
HU9600107D0 (en) 9-substituted-2-(2-n-alkoxy-phenyl)-purin-6-one derivatives
NZ332395A (en) Benzonthiazole derivatives
SI0758644T1 (sl) Derivati sulfonil- ali sulfinil-benzoil-gvanidina
SG60005A1 (en) 1-Fluorocyclohexene-difluorophenyl derivatives
HUP9900672A3 (en) Pyrroloazepine derivatives
IL123621A0 (en) Diarylalkenylamine derivatives
HK1003299A1 (en) Benzisothiazolyl-substituted aminomethylchroman derivatives
ZA964470B (en) Cycloalkane-benzylidene derivatives
IL117858A0 (en) 4-Indolypiperazinyl derivatives
GR3036572T3 (en) 4-amino-benzoylguanidine derivatives
HK1011013A1 (en) Fluorobenzylether derivatives
HU9602324D0 (en) Piperidinyl-methyl-oxazolidinon derivatives
ZA966665B (en) Aza-anthracyclinone derivatives
SI0725062T1 (en) 4-mercapto-benzoylguanidine derivatives
HK1003055A1 (en) Guanine derivative
GB2308593A (en) Imidazopyridedine derivatives